MNG1264
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.287
- PEROXISOME+0.245
- APICAL_SURFACE+0.189
- BILE_ACID_METABOLISM+0.183
- ESTROGEN_RESPONSE_LATE+0.169
- CHOLESTEROL_HOMEOSTASIS+0.158
- ESTROGEN_RESPONSE_EARLY+0.155
- KRAS_SIGNALING_DN+0.148
- HEME_METABOLISM+0.147
- XENOBIOTIC_METABOLISM+0.134
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.508
- INTERFERON_GAMMA_RESPONSE-0.481
- INTERFERON_ALPHA_RESPONSE-0.442
- IL6_JAK_STAT3_SIGNALING-0.436
- E2F_TARGETS-0.420
- G2M_CHECKPOINT-0.400
- MYC_TARGETS_V1-0.376
- MYC_TARGETS_V2-0.334
- INFLAMMATORY_RESPONSE-0.333
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.326
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | aMVAC.P_003_TURBT_S220 | — | — | 0.851 |
| 2 | SRR1430288 | GTEX | — | 0.841 |
| 3 | SRR1332796 | GTEX | — | 0.839 |
| 4 | ERR2208949 | — | — | 0.837 |
| 5 | MNG1052 | — | — | 0.834 |
| 6 | SRR8613724 | — | F | 0.832 |
| 7 | SRR1343481 | GTEX | — | 0.831 |
| 8 | SRR25617843 | — | B | 0.830 |
| 9 | SRR6079984 | — | — | 0.825 |
| 10 | TCGA-CF-A3MH-01A-11R-A20F-07 | — | — | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.287 | Inavolisib | — uncovered |
| PEROXISOME | 0.245 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.189 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.183 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.169 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.158 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.155 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.148 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.147 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.134 | Inavolisib | — uncovered |
| MYOGENESIS | 0.133 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.133 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.101 | Inavolisib | — uncovered |
| COAGULATION | 0.077 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.068 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.067 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.028 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.018 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.015 | Inavolisib | — uncovered |